Evidence map›Paper›PMID 27015966›Full record

Trial reportContemporary clinical trials2016

Enhancing panic and smoking reduction treatment with d-cycloserine: Study protocol for a randomized controlled trial.

Jasper A J Smits, Brooke Y Kauffman, Eunjung Lee-Furman, Michael J Zvolensky, Michael W Otto, Megan E Piper, Mark B Powers, David Rosenfield

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jasper A J SmitsDepartment of Psychology, Institute for Mental Health Research, University of Texas at Austin, Austin, TX, United States. Electronic address: smits@utexas.edu.
Brooke Y KauffmanDepartment of Psychology, University of Houston, Houston, TX, United States.
Eunjung Lee-FurmanDepartment of Psychology, Institute for Mental Health Research, University of Texas at Austin, Austin, TX, United States.
Michael J ZvolenskyDepartment of Psychology, University of Houston, Houston, TX, United States; Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Michael W OttoPsychological and Brain Sciences, Boston University, Boston, MA, United States.
Megan E PiperCenter for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Mark B PowersDepartment of Psychology, Institute for Mental Health Research, University of Texas at Austin, Austin, TX, United States.
David RosenfieldDepartment of Psychology, Southern Methodist University, Dallas, TX, United States.

Funding

Integrated PTSD and Smoking TreatmentK01DA035930 · NIDA · UNIVERSITY OF TEXAS AT AUSTIN · PI POWERS, MARK B · 2013 to 2017
$857k
Enhancing Panic and Smoking Reduction Treatment with D-CycloserineR34DA034658 · NIDA · UNIVERSITY OF TEXAS AT AUSTIN · PI OTTO, MICHAEL W., SMITS, JASPER · 2013 to 2015
$622k
Personalized Feedback for Distress Intolerant SmokersF31DA046127 · NIDA · UNIVERSITY OF HOUSTON · PI REDMOND, BROOKE Y · 2018 to 2020
$107k
NIDA NIH HHS F31 DA046127NIDA NIH HHS K01 DA035930NIDA NIH HHS R34 DA034658
6 · The paper itself

Abstract

There has been relatively little attention focused on treatment strategies for smokers with panic attacks despite their increased risk of relapse. Panic and Smoking Reduction Treatment (PSRT) integrates standard smoking cessation treatment with an exposure-based intervention targeting the mechanisms underlying panic-smoking relations. Building upon emerging evidence supporting the efficacy of d-cycloserine (DCS) for augmenting exposure-based therapy, we are conducting an initial test of the efficacy of DCS for enhancing PSRT outcomes. Utilizing a randomized, double-blind trial comparing PSRT+DCS to PSRT+placebo, we will obtain initial effect sizes for short-term and long-term smoking cessation outcomes and perform an initial test of putative mechanisms.

Indexed as

AntimetabolitesCycloserineDouble-Blind MethodHumansImplosive TherapyPanic DisorderSmokingSmoking CessationAntimetabolitesCycloserineAugmentationBehavioral interventionClinical triald-CycloserinePanicSmoking cessation

Identifiers

PMID27015966
PMCPMC4885779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.